<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015912</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02379</org_study_id>
    <secondary_id>00-171; CWRU 5Y99</secondary_id>
    <secondary_id>CDR0000068572</secondary_id>
    <nct_id>NCT00015912</nct_id>
  </id_info>
  <brief_title>Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC #66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in&#xD;
      treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may&#xD;
      stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere&#xD;
      with the growth of cancer cells. Combining thalidomide with interferon alfa may kill more&#xD;
      tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of interferon alfa and thalidomide, in terms of response rate, time&#xD;
      to progression, and overall survival, in patients with relapsed or refractory low-grade&#xD;
      follicular non-Hodgkin's lymphoma.&#xD;
&#xD;
      II. Determine the quantitative and qualitative toxic effects of this regimen in this patient&#xD;
      population.&#xD;
&#xD;
      III. Correlate ancillary biological studies with clinical endpoints in these patients treated&#xD;
      with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in&#xD;
      the absence of disease progression or unacceptable toxicity. Patients are followed every 6&#xD;
      months until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete and partial)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier estimates will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier estimates will be determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (interferon-alpha, thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (interferon-alpha, thalidomide)</arm_group_label>
    <other_name>Alferon N</other_name>
    <other_name>alpha interferon</other_name>
    <other_name>IFN-A</other_name>
    <other_name>Intron A</other_name>
    <other_name>Roferon-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (interferon-alpha, thalidomide)</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (interferon-alpha, thalidomide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed relapsed or refractory low-grade follicular non-Hodgkin's&#xD;
             lymphoma (NHL)&#xD;
&#xD;
               -  WHO grade 1 or 2&#xD;
&#xD;
               -  Failure to achieve a complete or partial remission after prior treatment regimen&#xD;
&#xD;
               -  Relapse or disease progression within 30 days after prior treatment regimen&#xD;
&#xD;
          -  No histologic transformation to aggressive NHL or areas of diffuse NHL&#xD;
&#xD;
          -  At least 1 measurable lesion by CT scan, MRI, or chest x-ray&#xD;
&#xD;
          -  Tissue in the form of tissue blocks available&#xD;
&#xD;
          -  No brain metastasis or primary brain tumors&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.5 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  PT (or INR)/PTT normal or not clinically significant&#xD;
&#xD;
          -  No preexisting liver disease&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No uncompensated coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction or severe/unstable angina within the past 6 months&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No prior gastrointestinal disorder that would interfere with thalidomide absorption&#xD;
&#xD;
          -  No preexisting autoimmune disease&#xD;
&#xD;
          -  No medical, psychological, or social problem that would preclude study participation&#xD;
&#xD;
          -  No uncontrolled or untreated depression&#xD;
&#xD;
          -  No emotional disorder or substance abuse&#xD;
&#xD;
          -  No prior seizures or potential risk factors for development of seizures&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test at baseline, weekly for 4 weeks, and then every 2-4 weeks&#xD;
             thereafter while on study&#xD;
&#xD;
          -  Fertile female patients must use 1 highly active method and 1 additional effective&#xD;
             method of contraception for 4 weeks before, during, and for 4 weeks after study&#xD;
&#xD;
          -  Fertile male patients must use effective barrier contraception during and for 4 weeks&#xD;
             after study participation&#xD;
&#xD;
          -  No more than 1 prior course of unconjugated monoclonal antibody therapy&#xD;
&#xD;
          -  No prior conjugated monoclonal antibody (radiolabeled or immunotoxin) therapy&#xD;
&#xD;
          -  No prior interferon alfa&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors or other cytokines&#xD;
&#xD;
          -  No concurrent monoclonal antibodies&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens (single agent or combination)&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  At least 28 days since prior corticosteroid therapy&#xD;
&#xD;
          -  Prior or concurrent megestrol allowed&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  Prior palliative radiotherapy to nontarget lesions allowed&#xD;
&#xD;
          -  No prior radiotherapy to all sites of measurable disease&#xD;
&#xD;
          -  No prior extensive radiotherapy to more than 20% of bone marrow&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  At least 14 days since prior major surgery&#xD;
&#xD;
          -  No prior major upper gastrointestinal surgery&#xD;
&#xD;
          -  No other concurrent cytotoxic agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sweetenham</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>October 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

